Denali Therapeutics, Inc. (DNLI)
20.22
+0.84
(+4.31%)
USD |
NASDAQ |
May 27, 16:00
20.15
-0.06
(-0.32%)
After-Hours: 18:34
Denali Therapeutics Cash from Investing (Quarterly) : 94.46M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -209.50M |
| Neurocrine Biosciences, Inc. | -506.20M |
| Arcturus Therapeutics Holdings, Inc. | 0.034M |
| Agenus, Inc. | 68.95M |
| Curis, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -131.20M |
| Cash from Financing (Quarterly) | 219.04M |
| Free Cash Flow | -419.23M |
| Free Cash Flow Per Share (Quarterly) | -0.7162 |
| Free Cash Flow to Equity (Quarterly) | -131.43M |
| Free Cash Flow to Firm (Quarterly) | -133.67M |
| Free Cash Flow Yield | -11.75% |